Integra Lifesciences (IART)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 276,402 | 273,732 | 309,192 | 307,367 | 456,661 |
| Marketable Securities | 32,694 | N/A | N/A | N/A | N/A |
| Receivables | 259,327 | 256,270 | 258,663 | 253,995 | 263,465 |
| Inventories | 389,608 | 366,251 | 354,293 | 351,275 | 324,583 |
| Other current assets | 32,643 | 0 | 0 | 0 | 31,032 |
| TOTAL | $1,058,036 | $1,027,229 | $1,051,260 | $1,029,482 | $1,161,498 |
| Non-Current Assets | |||||
| PPE Net | 340,199 | 318,718 | 317,571 | 315,175 | 311,302 |
| Intangibles | 2,123,295 | 2,103,169 | 2,136,869 | 2,150,365 | 2,165,490 |
| Other Non-Current Assets | 260,458 | 290,255 | 271,901 | 247,377 | 251,468 |
| TOTAL | $2,723,952 | $2,712,142 | $2,726,341 | $2,712,917 | $2,728,260 |
| Total Assets | $3,781,988 | $3,739,371 | $3,777,601 | $3,742,399 | $3,889,758 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 75,700 | 90,800 | N/A | N/A |
| Accounts payable and accrued liabilities | 92,326 | 93,550 | 99,766 | 112,785 | 102,100 |
| Accrued Expenses | 176,299 | 154,175 | 159,193 | 146,973 | 158,804 |
| Other current liabilities | 8,540 | 8,139 | 8,275 | 7,743 | 7,253 |
| TOTAL | $306,980 | $355,712 | $377,496 | $282,293 | $320,906 |
| Non-Current Liabilities | |||||
| Long Term Debt | 914,763 | 850,089 | 764,616 | 871,643 | 837,849 |
| Other Non-Current Liabilities | 937,044 | 879,896 | 881,676 | 851,832 | 863,262 |
| TOTAL | $1,887,124 | $1,804,438 | $1,716,945 | $1,785,168 | $1,764,449 |
| Total Liabilities | $2,194,104 | $2,160,150 | $2,094,441 | $2,067,461 | $2,085,355 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 78,220 | 78,176 | 81,404 | 81,904 | 81,636 |
| Common Shares | 909 | 909 | 909 | 908 | 905 |
| Retained earnings | 946,859 | 927,025 | 907,528 | 903,344 | 879,118 |
| Other shareholders' equity | -15,368 | 1,968 | 5,048 | 7,389 | 10,403 |
| TOTAL | $1,587,884 | $1,579,221 | $1,683,160 | $1,674,938 | $1,804,403 |
| Total Liabilities And Equity | $3,781,988 | $3,739,371 | $3,777,601 | $3,742,399 | $3,889,758 |